Today, during the meeting of Vladimir Putin with pharmaceutical companies, President of Nanolek, Vladimir Khristenko, confirmed that by the end of 2021, the company’s plant in the Kirov Region plans to produce from 5 million doses of the CoviVac vaccine against the coronavirus.

Khristenko added that within the framework of a strategic partnership with the RI named after Chumakov, Nanolek would invest 40 million roubles in technology transfer and scaling up of CoviVac production. The production of the vaccine will begin in the summer of 2021.

“Fortunately, we had begun to prepare the line for the production of the vaccine against the coronavirus long before the pandemic. Together with the Research Institute named after Chumakov - the developer of CoviVac - we have been working on releasing a completely domestic inactivated polio vaccine for two years now. And we are lucky that the production of the CoviVac vaccine is carried out using practically the same technology,” commented the President of Nanolek.

The Nanolek plant in the Kirov Region, opened in 2014, was built with an eye to the world’s best practices and technologies. The production holds GMP certificate and regularly undergoes quality audits of sizeable international pharmaceutical corporations: the Nanolek plant manufactures products for companies such as Sanofi, Janssen, Merck, and others.

NANOLEK SUMMERY

Nanolek is a modern biopharmaceutical company, one of the leaders in the production of pediatric vaccines in Russia. It was founded in 2011 by Vladimir Khristenko and Mikhail Nekrasov. The company specializes in the production of import-substituting and innovative medicines, both of its design and created with international partners’ involvement. In addition to vaccines, the portfolio includes medications to treat HIV, cancer, and orphan diseases.

Vladimir Khristenko. The co-founder of Nanolek. Since 2015, he has been the president of the company. V. Khristenko is responsible for strategic development, forming a portfolio of medicines, and interaction with international partners. Prior to joining pharmaceuticals, Vladimir Khristenko held executive positions in the Chelyabinsk Pipe Rolling Plant group of CTRP. Graduated from the Higher School of Economics with a degree in Finance and Credit, he has a Ph.D. in Economics. In 2016, Vladimir completed training for top management at the University of Chicago Booth School of Business.